Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 1.00 |
| ▸ | RAF1 | P04049 | 9/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 10/20 | 0.81 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.81 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.81 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.81 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.70 |
| ▸ | GCGR | P47871 | 2/20 | 0.70 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7643418 | 1.00 | BRAF (1.00) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| Bromide SCHEMBL7648283 | 0.97 | BRAF (0.95) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL7648286 | 0.95 | BRAF (0.91) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL12856388 | 0.95 | BRAF (0.90) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL28403334 | 0.90 | MAPK13 (1.00) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL2214546 | 0.85 | BRAF (1.00) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL2649589 | 0.84 | MAPK13 (0.90) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL15075633 | 0.84 | BRAF (0.91) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL7645951 | 0.83 | MAPK13 (0.74) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL20242995 | 0.82 | RAF1 (0.70) | BRAFRAF1MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 574 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS INC (US) | 2026-01-22 | — | — | US | claimed |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | YALE UNIVERSITY (US) | 2025-12-02 | — | — | US | claimed |
| US-20250332274-A1 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | UNIV YALE (US) | 2025-10-30 | — | — | US | claimed |
| US-12364766-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | YALE UNIVERSITY (US) | 2025-07-22 | — | — | US | claimed |
| CN-119591582-A | Imide-based proteolytic modulators and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-119591543-A | Bis-aminoquinolines and nano-formulations for cancer treatment | 加利福尼亚大学董事会 | 2025-03-11 | — | — | CN | claimed |
| EP-4493222-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Yale University (US) | 2025-01-22 | — | — | EP | claimed |
| CN-119255822-A | Bifunctional small molecules targeting selective degradation of circulating proteins | 耶鲁大学 | 2025-01-03 | — | — | CN | claimed |
| CN-115974840-A | Human cereblon ligand and bifunctional compound comprising same | 阿尔维纳斯运营股份有限公司 | 2023-04-18 | — | — | CN | claimed |
| US-20230097887-A1 | Bi-functional Molecules to Degrade Circulating Proteins | YALE UNIVERSITY | 2023-03-30 | — | — | US | claimed |
| US-20230083388-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-03-16 | — | — | US | claimed |
| US-11512083-B2 | Compounds and methods for the enhanced degradation of targeted proteins | ARVINAS OPERATIONS, INC. (US) | 2022-11-29 | — | — | US | claimed |
| WO-2022169634-A9 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-09-22 | — | — | WO | claimed |
| CN-115023418-A | Bis-aminoquinoline and nanoformulation for cancer treatment | 加利福尼亚大学董事会 | 2022-09-06 | — | — | CN | claimed |
| US-20220267329-A1 | Dihydro-Spiro[Indoline-3:1'-Isoquinolin]-2-Ones and Their Analogues and Derivatives and Methods of Treating Cancer and Other Diseases | THE UNIV OF BUEA (CM) | 2022-08-25 | — | — | US | claimed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | claimed |
| EP-4031543-A1 | BIAMINOQUINOLINES AND NANOFORMULATIONS FOR CANCER TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-27 | — | — | EP | claimed |
| US-20220089570-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. | 2022-03-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11512083-B2 | Compounds and methods for the enhanced degradation of targeted proteins | VHL, MDM2, XIAP | BRAF 1882/4885RAF1 1227/4885MAPK13 3940/4885 |
| US-20230097887-A1 | Bi-functional Molecules to Degrade Circulating Proteins | MIF, GMFG, SERPINA6 | BRAF 1506/4885RAF1 2236/4885MAPK13 2754/4885 |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | VHL, ADRM1, MDM2 | BRAF 1058/4885RAF1 581/4885MAPK13 3324/4885 |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | ASGR1, LDLR, FCGR2A | BRAF 3788/4885RAF1 3278/4885MAPK13 4207/4885 |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | MDM2, UBR4, UBE3A | BRAF 1811/4885RAF1 1506/4885MAPK13 1388/4885 |
| US-20250332274-A1 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | ASGR1, LDLR, FCGR3B | BRAF 3479/4885RAF1 2991/4885MAPK13 4298/4885 |
| US-20230083388-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | BRAF 3788/4885RAF1 3278/4885MAPK13 4207/4885 |
| US-20220089570-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | BRAF 2005/4885RAF1 1579/4885MAPK13 3199/4885 |
| US-20220267329-A1 | Dihydro-Spiro[Indoline-3:1'-Isoquinolin]-2-Ones and Their Analogues and Derivatives and Methods of Treating Cancer and Other Diseases | S1PR3, S1PR1, S1PR2 | BRAF 1055/4885RAF1 721/4885MAPK13 4111/4885 |
| US-12364766-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | ASGR1, LDLR, FCGR3B | BRAF 3479/4885RAF1 2991/4885MAPK13 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.